PPTC7

Summary

PPTC7 (protein phosphatase targeting COQ7, HGNC:30695) is a protein-coding gene on chromosome 12q24.11, encoding Protein phosphatase PTC7 homolog (Q8NI37). Protein phosphatase that plays an essential role in mitochondrial metabolism and biogenesis.

Enables protein serine/threonine phosphatase activity and protein-macromolecule adaptor activity. Involved in negative regulation of mitophagy and positive regulation of ubiquinone biosynthetic process. Located in mitochondrial matrix. Is active in mitochondrial outer membrane.

Source: NCBI Gene 160760 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 29 total — 1 pathogenic, 2 likely-pathogenic
• MANE Select transcript: NM_139283

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30695
Approved symbol	PPTC7
Name	protein phosphatase targeting COQ7
Location	12q24.11
Locus type	gene with protein product
Status	Approved
Aliases	TA-PP2C
Ensembl gene	ENSG00000196850
Ensembl biotype	protein_coding
OMIM	609668
Entrez	160760

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 retained_intron

ENST00000354300, ENST00000548721, ENST00000905428, ENST00000905429, ENST00000905430, ENST00000905431, ENST00000931173, ENST00000965725

RefSeq mRNA: 1 — MANE Select: NM_139283 NM_139283

CCDS: CCDS9149

Canonical transcript exons

ENST00000354300 — 6 exons

Exon	Start	End
ENSE00000938089	110545880	110546078
ENSE00001237630	110533245	110537095
ENSE00001512714	110582809	110583318
ENSE00001778958	110551789	110551968
ENSE00003675538	110538144	110538273
ENSE00003686491	110539822	110539945

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 99.58.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.3700 / max 428.2626, expressed in 1800 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
133245	18.8406	1800
133243	0.4924	98
133244	0.0370	14

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	99.58	gold quality
deltoid	UBERON:0001476	99.05	gold quality
tibialis anterior	UBERON:0001385	99.00	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	98.86	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.79	gold quality
vastus lateralis	UBERON:0001379	98.76	gold quality
biceps brachii	UBERON:0001507	98.72	gold quality
heart right ventricle	UBERON:0002080	98.58	gold quality
body of tongue	UBERON:0011876	98.45	gold quality
myocardium	UBERON:0002349	98.41	gold quality
secondary oocyte	CL:0000655	98.36	gold quality
kidney epithelium	UBERON:0004819	98.34	gold quality
quadriceps femoris	UBERON:0001377	98.32	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	98.19	gold quality
tongue	UBERON:0001723	97.79	gold quality
skeletal muscle tissue	UBERON:0001134	97.45	gold quality
palpebral conjunctiva	UBERON:0001812	97.38	gold quality
nasal cavity epithelium	UBERON:0005384	97.31	gold quality
upper arm skin	UBERON:0004263	96.92	gold quality
visceral pleura	UBERON:0002401	96.90	gold quality
epithelial cell of pancreas	CL:0000083	96.85	gold quality
cauda epididymis	UBERON:0004360	96.85	gold quality
superior surface of tongue	UBERON:0007371	96.82	gold quality
lateral nuclear group of thalamus	UBERON:0002736	96.77	gold quality
substantia nigra pars compacta	UBERON:0001965	96.75	gold quality
trachea	UBERON:0003126	96.62	gold quality
epithelium of nasopharynx	UBERON:0001951	96.55	gold quality
vena cava	UBERON:0004087	96.53	gold quality
pons	UBERON:0000988	96.49	gold quality
mammalian vulva	UBERON:0000997	96.40	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

210 targeting PPTC7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-5688	99.96	73.23	4504

Literature-anchored findings (GeneRIF, showing 3)

• Microarray evidence for coexpression of TA-PP2C with IL2 in T-cells and other cell types. (PMID:15177553)
• PPTC7 is a regulatory protein of CoQ10 biosynthesis required for human cell survival. (PMID:30267671)
• PPTC7 antagonizes mitophagy by promoting BNIP3 and NIX degradation via SCF[FBXL4]. (PMID:38992176)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	pptc7a	ENSDARG00000011122
danio_rerio	pptc7b	ENSDARG00000052658
mus_musculus	Pptc7	ENSMUSG00000038582
rattus_norvegicus	Pptc7	ENSRNOG00000021440
drosophila_melanogaster	CG15035	FBGN0029949
drosophila_melanogaster	CG12091	FBGN0035228
drosophila_melanogaster	fig	FBGN0039694
caenorhabditis_elegans		WBGENE00012362

Protein

Protein identifiers

Protein phosphatase PTC7 homolog — Q8NI37 (reviewed: Q8NI37)

Alternative names: T-cell activation protein phosphatase 2C, T-cell activation protein phosphatase 2C-like

All UniProt accessions (1): Q8NI37

UniProt curated annotations — full annotation on UniProt →

Function. Protein phosphatase that plays an essential role in mitochondrial metabolism and biogenesis. Positively regulates biosynthesis of the ubiquinone, coenzyme Q. Dephosphorylates the ubiquinone biosynthesis protein COQ7 which is likely to lead to its activation. Serves as a crucial sensor for mitophagy, though the underlying mechanism remains ambiguous. May dephosphorylate BNIP3 and NIX and thereby directly regulates mitophagy receptor function and stability. Alternatively, promotes SCF-FBXL4-dependent ubiquitination and degradation of BNIP3 and NIX independently of its catalytic activity to restrain mitophagy.

Subunit / interactions. Interacts with FBXL4, BNIP3 and NIX; these interactions are important for ubiquitination and degradation of BNIP3 and NIX.

Subcellular location. Mitochondrion matrix.

Tissue specificity. Expressed in keratinocytes (at protein level).

Activity regulation. Inhibited by sodium orthovanadate.

Cofactor. Binds 2 magnesium or manganese ions per subunit.

Induction. By hydrogen peroxide and nutrional stress (such as low glucose). Up-regulated during lymphocyte activation.

Similarity. Belongs to the PP2C family.

RefSeq proteins (1): NP_644812* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001932	PPM-type_phosphatase-like_dom	Domain
IPR036457	PPM-type-like_dom_sf	Homologous_superfamily
IPR039123	PPTC7	Family

Pfam: PF07228

Catalyzed reactions (Rhea), 2 shown:

• O-phospho-L-seryl-[protein] + H2O = L-seryl-[protein] + phosphate (RHEA:20629)
• O-phospho-L-threonyl-[protein] + H2O = L-threonyl-[protein] + phosphate (RHEA:47004)

UniProt features (10 total): binding site 4, sequence conflict 3, transit peptide 1, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NI37-F1	88.84	0.82

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 78; 78; 79; 223

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 216 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, MODULE_97, GOBP_REGULATION_OF_AUTOPHAGY, TGCGCANK_UNKNOWN, AREB6_03, MODULE_182, TGACCTY_ERR1_Q2, GOBP_KETONE_METABOLIC_PROCESS, GOBP_MACROAUTOPHAGY, COUP_01, GOBP_NEGATIVE_REGULATION_OF_AUTOPHAGY, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_REGULATION_OF_KETONE_METABOLIC_PROCESS, HEN1_01

GO Biological Process (4): regulation of ubiquinone biosynthetic process (GO:0010795), negative regulation of mitophagy (GO:1901525), positive regulation of ubiquinone biosynthetic process (GO:1904775), mitophagy (GO:0000423)

GO Molecular Function (6): protein serine/threonine phosphatase activity (GO:0004722), protein-macromolecule adaptor activity (GO:0030674), metal ion binding (GO:0046872), phosphoprotein phosphatase activity (GO:0004721), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial outer membrane (GO:0005741), mitochondrial matrix (GO:0005759)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
ubiquinone biosynthetic process	2
regulation of ketone biosynthetic process	1
mitophagy	1
negative regulation of macroautophagy	1
regulation of mitophagy	1
negative regulation of autophagy of mitochondrion	1
positive regulation of biosynthetic process	1
regulation of ubiquinone biosynthetic process	1
positive regulation of small molecule metabolic process	1
autophagy of mitochondrion	1
macroautophagy	1
phosphoprotein phosphatase activity	1
protein binding	1
molecular adaptor activity	1
cation binding	1
phosphatase activity	1
catalytic activity, acting on a protein	1
binding	1
catalytic activity	1
cytoplasm	1
intracellular membrane-bounded organelle	1
mitochondrial membrane	1
organelle outer membrane	1
mitochondrion	1
intracellular organelle lumen	1

Protein interactions and networks

STRING

1640 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PPTC7	PDP1	Q9P0J1	894
PPTC7	PPM1A	P35813	807
PPTC7	PPM1K	Q8N3J5	616
PPTC7	COQ7	Q99807	567
PPTC7	PPM1M	Q96MI6	555
PPTC7	PPM1L	Q5SGD2	541
PPTC7	PPM1H	Q9ULR3	532
PPTC7	PPM1J	Q5JR12	503
PPTC7	PPM1F	P49593	500
PPTC7	ZER1	Q7Z7L7	476
PPTC7	PP2D1	A8MPX8	475
PPTC7	FAM216A	Q8WUB2	466
PPTC7	CNOT12	Q9C0C2	443
PPTC7	PDP2	Q9P2J9	432
PPTC7	COQ9	O75208	429
PPTC7	PPM1B	O75688	429

IntAct

62 interactions, top by confidence:

A	B	Type	Score
BNIP3	BNIP3L	psi-mi:“MI:0914”(association)	0.970
BNIP3	PPTC7	psi-mi:“MI:0915”(physical association)	0.800
TRMT61B	PPTC7	psi-mi:“MI:0914”(association)	0.710
ASF1B	HAT1	psi-mi:“MI:0914”(association)	0.640
ASF1A	HAT1	psi-mi:“MI:0914”(association)	0.640
PPTC7	PBXIP1	psi-mi:“MI:0915”(physical association)	0.560
BCL6	PPTC7	psi-mi:“MI:0915”(physical association)	0.560
PPTC7	DMWD	psi-mi:“MI:0915”(physical association)	0.560
PPTC7	NEFL	psi-mi:“MI:0915”(physical association)	0.560
PPTC7	WFS1	psi-mi:“MI:0915”(physical association)	0.560
PPTC7	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
FAM174A	BLTP3B	psi-mi:“MI:0914”(association)	0.530
LPAR4	POTEF	psi-mi:“MI:0914”(association)	0.530
TMEM9	ESYT2	psi-mi:“MI:0914”(association)	0.530
CD70	METTL15	psi-mi:“MI:0914”(association)	0.530
PPTC7	UBB	psi-mi:“MI:0914”(association)	0.530
PPTC7	ZDHHC17	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (96): PPTC7 (Two-hybrid), PPTC7 (Affinity Capture-MS), BNIP3 (Affinity Capture-MS), BNIP3L (Affinity Capture-MS), TRMT61B (Affinity Capture-MS), TRMT2B (Affinity Capture-MS), MRPL22 (Affinity Capture-MS), MRPS18C (Affinity Capture-MS), SARS2 (Affinity Capture-MS), SPHKAP (Affinity Capture-MS), C1QBP (Affinity Capture-MS), RTN4IP1 (Affinity Capture-MS), TRMT2B (Affinity Capture-MS), PPTC7 (Affinity Capture-MS), PPTC7 (Affinity Capture-MS)

ESM2 similar proteins: B3MTI8, B3P5D3, B4G653, B4HZE7, B4JYN1, B4K616, B4M5T5, B4NBL6, B4PPK3, B4R089, F4HYJ7, F4IDQ6, O14156, O14189, O15056, O55207, O82637, P38797, P39966, P49594, Q09189, Q29AP0, Q2QMG2, Q2R637, Q2RBJ6, Q5BJS0, Q5JJY4, Q5JKN1, Q5U3N5, Q5ZI74, Q6GR25, Q6H7J3, Q6H7J4, Q6NKS1, Q6NVE9, Q6Z8B9, Q75B12, Q7L2E3, Q7M753, Q7SHQ1

Diamond homologs: B3MTI8, B3P5D3, B4G653, B4HZE7, B4JYN1, B4K616, B4M5T5, B4NBL6, B4PPK3, B4R089, O64730, P38797, Q09189, Q10QL5, Q29AP0, Q339D2, Q5U3N5, Q6GR25, Q6H7J3, Q6H7J4, Q6J2K6, Q6NVE9, Q8NI37, Q93V88, Q942P9, Q9LVQ8, Q9SUK9, Q9VAH4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 54 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
nucleosome assembly	5	14.6×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	2
Uncertain significance	19
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
980454	GRCh37/hg19 12q23.3-24.12(chr12:106498814-112252906)x1	Pathogenic
4813198	NM_139283.2(PPTC7):c.472G>A (p.Asp158Asn)	Likely pathogenic
4813199	NM_139283.2(PPTC7):c.*57dup	Likely pathogenic

SpliceAI

1380 predictions. Top by Δscore:

Variant	Effect	Δscore
12:110538271:ATTC:A	acceptor_loss	1.0000
12:110538272:TT:T	acceptor_gain	1.0000
12:110538273:TCT:T	acceptor_loss	1.0000
12:110538274:C:CC	acceptor_gain	1.0000
12:110538274:CTAAG:C	acceptor_loss	1.0000
12:110539817:ATTAC:A	donor_loss	1.0000
12:110539818:TTA:T	donor_loss	1.0000
12:110539820:A:C	donor_loss	1.0000
12:110539821:C:CG	donor_loss	1.0000
12:110539823:TTTA:T	donor_gain	1.0000
12:110539827:A:C	donor_gain	1.0000
12:110539941:CCGGA:C	acceptor_gain	1.0000
12:110539942:CGGA:C	acceptor_gain	1.0000
12:110539942:CGGAC:C	acceptor_gain	1.0000
12:110539943:GGA:G	acceptor_gain	1.0000
12:110539943:GGACT:G	acceptor_loss	1.0000
12:110539944:GA:G	acceptor_gain	1.0000
12:110539945:AC:A	acceptor_loss	1.0000
12:110539946:C:CC	acceptor_gain	1.0000
12:110539948:G:C	acceptor_gain	1.0000
12:110539952:C:CT	acceptor_gain	1.0000
12:110539953:A:T	acceptor_gain	1.0000
12:110539958:C:CT	acceptor_gain	1.0000
12:110539959:A:T	acceptor_gain	1.0000
12:110545876:TTA:T	donor_loss	1.0000
12:110545877:TACCT:T	donor_loss	1.0000
12:110545878:AC:A	donor_loss	1.0000
12:110546076:TACCT:T	acceptor_loss	1.0000
12:110546077:ACCTA:A	acceptor_loss	1.0000
12:110546079:CTAGA:C	acceptor_loss	1.0000

AlphaMissense

1966 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:110537063:A:G	S297P	1.000
12:110537080:T:A	D291V	1.000
12:110537083:T:A	D290V	1.000
12:110537084:C:G	D290H	1.000
12:110537088:C:A	K288N	1.000
12:110537088:C:G	K288N	1.000
12:110537092:C:T	G287E	1.000
12:110538181:A:C	F273L	1.000
12:110538181:A:T	F273L	1.000
12:110538182:A:C	F273C	1.000
12:110538183:A:G	F273L	1.000
12:110539864:G:C	N228K	1.000
12:110539864:G:T	N228K	1.000
12:110539868:T:A	D227V	1.000
12:110539868:T:G	D227A	1.000
12:110539877:C:T	G224E	1.000
12:110539878:C:G	G224R	1.000
12:110539878:C:T	G224R	1.000
12:110539879:A:C	D223E	1.000
12:110539879:A:T	D223E	1.000
12:110539880:T:A	D223V	1.000
12:110539880:T:C	D223G	1.000
12:110539880:T:G	D223A	1.000
12:110539881:C:G	D223H	1.000
12:110539883:G:A	T222I	1.000
12:110539886:G:T	A221E	1.000
12:110539895:A:T	I218N	1.000
12:110539901:T:A	D216V	1.000
12:110539901:T:C	D216G	1.000
12:110539901:T:G	D216A	1.000

dbSNP variants (sampled 300 via entrez): RS1000298667 (12:110564243 T>C), RS1000307267 (12:110565010 G>A), RS1000341259 (12:110541312 A>G), RS1000380052 (12:110582273 T>C), RS1000440394 (12:110548138 T>C), RS1000472340 (12:110562899 A>G), RS1000494151 (12:110577025 G>A), RS1000567735 (12:110562396 A>G), RS1000581283 (12:110581157 C>T), RS1000626338 (12:110563894 G>A), RS1000646299 (12:110540398 T>G), RS1000727191 (12:110541604 G>A), RS1000734592 (12:110556633 G>A), RS1000771668 (12:110546651 T>C), RS1000882545 (12:110581945 A>G)

Disease associations

OMIM: gene MIM:609668 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
Arsenic	affects expression, affects methylation, affects cotreatment, increases abundance, increases expression	2
Estradiol	increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cadmium Chloride	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	increases expression	1
triphenyl phosphate	affects expression	1
pirinixic acid	increases expression, affects binding, increases activity	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
zinc chromate	increases abundance, increases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
hydroquinone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, increases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, affects expression	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	increases abundance, increases expression	1
Doxorubicin	decreases expression	1
Chlorpyrifos	decreases expression, decreases response to substance	1
Formaldehyde	decreases expression	1
Manganese	increases expression, affects cotreatment, increases abundance	1
Methyl Methanesulfonate	decreases expression	1
Ozone	affects expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TG34	HAP1 PPTC7 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice